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BACKGROUND: The detection, enumeration and isolation of circulating tumour cells (CTCs) have considerable potential to influence
the clinical management of patients with breast cancer. There is, however, substantial variability in the rates of positive samples
using existing detection techniques. The lack of standardisation of technology hampers the implementation of CTC measurement in
clinical routine practice.
METHODS: This study was designed to directly compare three techniques for detecting CTCs in blood samples taken from 76 patients
with metastatic breast cancer (MBC) and from 20 healthy controls: the CellSearch CTC System, the AdnaTest Breast Cancer Select/
Detect and a previously developed real-time qRT-PCR assay for the detection of CK-19 and mammaglobin transcripts.
RESULTS: As a result, 36% of patients with MBC were positive by the CellSearch System, 22% by the AdnaTest, 26% using RT–PCR
for CK-19 and 54% using RT–PCR for mammaglobin. Samples were significantly more likely to be positive for at least one mRNA
marker using RT–PCR than using the CellSearch System (P¼0.001) or the AdnaTest (Po0.001).
CONCLUSION: We observed a substantial variation in the detection rates of CTCs in blood from breast cancer patients using
three different techniques. A higher rate of positive samples was observed using a combined qRT-PCR approach for CK-19
and mammaglobin, which suggests that this is currently the most sensitive technique for detecting CTCs.
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Metastasis is the leading cause of breast cancer-related deaths, but
early spread of tumour cells usually remains undetected even by
high-resolution imaging technologies. Traditional prognostic
factors do not accurately predict which patients will eventually
relapse after primary treatment, and provide only limited
information on the effectiveness of adjuvant treatment. Accumu-
lating reports show that the detection of circulating tumour cells
(CTCs) in body fluids has considerable potential to improve the
clinical management of patients with breast cancer (Cristofanilli
et al, 2004, 2005; Budd et al, 2006; Hayes et al, 2006; Wong et al,
2006; Benoy et al, 2006a; Rack et al, 2009). Over the past few years,
different approaches for the detection, enumeration and isolation
of CTCs in blood have been developed. Immunocytochemical
analysis is usually used in combination with density-gradient
centrifugation (Balic et al, 2005; Muller et al, 2005; Wiedswang
et al, 2006), size filtration (Kahn et al, 2004; Wong et al, 2006) or
flow cytometry (Meng et al, 2004; Allan et al, 2005) to enrich
tumour cells before their detection. In addition, nucleic-acid-based
approaches for cell detection have been described (Lambrechts
et al, 1999; Smith et al, 2000; Aerts et al, 2001; Stathopoulou et al,
2002; Benoy et al, 2004). There is, however, substantial variability
with regard to the rates of positive samples using existing
techniques. Lack of standardisation of technology hampers the
implementation of CTC measurement in clinical routine practice.
This study was designed to directly compare three techniques
for detecting CTCs in the blood of patients with metastatic breast
cancer (MBC). The first technique is called the CellSearch System
(Veridex LLC, Raritan, NJ, USA), developed to automatically
enrich and immunocytochemically detect CTCs from peripheral
blood (Allard et al, 2004), and is currently the only instrument
with regulatory approval for routine clinical use in MBC patients.
This system consists of CellSave Preservative tubes, preventing
CTC degradation for up to 96h; the CellSearch CTC kit, a pre-
packaged kit for the isolation and identification of CTCs;
CellSearch control cells for assuring proper performance on a
daily or run-to-run basis; the CellTracks AutoPrep system for
automatically adding reagents and the CellTracks Analyzer II, a
semi-automated microscope for scanning and reading results.
Epithelial cells are immunomagnetically separated and fluores-
cently labelled, and nucleated (DAPIþ) cells with the EpCAMþ,
cytokeratin (CK) 8/18/19þ and CD45  phenotype are counted as
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sCTCs. Riethdorf et al (2007) validated the CellSearch System in a
multi-centre study and concluded that the system allows the
reliable detection of CTCs in blood and is suitable for the routine
assessment of MBC patients in a clinical laboratory. In a study by
Cristofanilli et al (2004, 2005), 177 patients with MBC were tested
for the presence of CTCs using the CellSearch System. The study
concluded that detection of CTCs before initiation of first-line
therapy in patients with MBC is highly predictive of progression-
free and overall survival. Furthermore, it was recently shown that
CTCs persisting after cytostatic, endocrine and zoledronate
treatment can be observed in a relevant number of clinically
recurrence-free breast cancer patients. A longer follow-up of these
patients will provide further insight in their prognostic relevance
and show whether they can be used for real-time tumour
phenotyping or serve as treatment target (Rack et al, 2009). The
second CTC detection method is the AdnaTest Breast Cancer
Select/Detect (AdnaGen AG, Langenhagen, Germany), in which
immunomagnetic separation is followed by a multiplex RT–PCR
for the tumour-associated transcripts HER2, Muc-1 and GA773-2.
This method has been shown to be a highly sensitive approach
with a detection limit of two tumour cells (Zieglschmid et al, 2005).
Using this technique, CTCs were detected in 69% of patients with
MBC (Zieglschmid et al, 2007a). The clinical validation of this
diagnostic system in breast cancer has not yet been reported.
However, in colorectal cancer, the presence of CTCs detected by
the AdnaTest Colon Cancer Select/Detect technique in the
peripheral blood collected before surgery, as well as in follow-up
samples, provided prognostic information (Zieglschmid et al,
2007b).
The final method of analysis is a multimarker real-time qRT-
PCR assay. This assay has been previously developed in our
laboratory for the detection of CK-19 and mammaglobin trans-
cripts in peripheral blood and bone marrow samples of patients
with breast cancer (Benoy et al, 2004). CK-19 is expressed in the
majority of breast carcinomas (Bartek et al, 1985) and has been
extensively used as a marker for CTC (Slade et al, 1999; Smith et al,
2000; Aerts et al, 2001; Stathopoulou et al, 2003; Benoy et al, 2004;
Ring et al, 2005). The specificity of mammaglobin for the detection
of breast cancer cells in haematopoietic products has been
evaluated in several studies (Leygue et al, 1999; Zach et al, 1999;
Suchy et al, 2000; Corradini et al, 2001; Silva et al, 2002; Lin et al,
2003). In a recent study, we observed that the detection of CK-19
and mammaglobin transcripts in bone marrow samples from
untreated patients with breast cancer was superior to immunocyto-
chemistry in predicting patients’ prognosis (Benoy et al, 2006a,b).
Kaplan–Meier survival analysis showed a markedly reduced
overall survival among patients with elevated CK-19 and mamma-
globin mRNA levels in bone marrow. However, the presence of
CTC in blood had no impact on patients’ overall survival.
MATERIALS AND METHODS
Patients and sample collection
We obtained peripheral blood samples from 76 patients with MBC
and from 20 healthy volunteers. All patients gave informed consent
for the use of their blood specimen, and examination of blood
samples was carried out after approval from the institutional
review board of the General Hospital Sint-Augustinus (Antwerp,
Belgium). Blood samples were taken from 60 patients receiving
treatment for MBC (treated patients) and from 16 patients who
presented themselves at our clinic with untreated MBC (untreated
patients). Treated patients received different cytostatic treatments
mostly containing taxanes, vinorelbine, anthracyclines or capeci-
tabine (N¼40), endocrine therapy (N¼17) or trastuzumab alone
or in combination with other treatments (N¼18). Most patients
were extensively pretreated. Samples were taken at least 3 weeks
after previous chemotherapy administration, and all patients were
sampled only once. The median age of the control population was
39 (range, 25–54) years and 62 (range, 34–85) years in the breast
cancer population. Clinicopathological variables were entered in a
database and are listed in Table 1. Disease status was assessed
using the Response Evaluation Criteria in Solid Tumours Group
(RECIST) criteria without knowledge of the patients’ CTC results
(Therasse et al, 2000). Disease status was subsequently dichot-
omised into either progressive (RECIST: PD) or non-progressive
disease (RECIST: SD, PR, CR). The study was conducted in a
double-blinded manner: the patients’ disease status was not known
to individuals who performed the blood assays (IVdA, DP, IB, HE
and SVL) and assay results were not known to the individual who
recorded the disease status (PVD, PH, AP and LD). The AdnaTest
Breast Cancer Select/Detect technique was performed indepen-
dently of the other two CTC assays by the Laboratory for Molecular
Biology (IB) (Labo Lokeren, Campus RIATOL, Antwerp, Belgium),
which was blinded to the other assay results.
CellSearch CTC test
Peripheral blood (10ml) was collected from each donor into
CellSave blood collection tubes (Immunicon Inc., Huntingdon
Valley, PA, USA), which are evacuated blood draw tubes contain-
ing EDTA and a cellular preservative, and processed within a
maximum of 72h after blood drawing (at room temperature).
Circulating tumour cells were enumerated with the CellSearch
System (Veridex, Raritan, NJ, USA) as described by Allard et al (2004).
Briefly, 7.5ml of blood was gently mixed with 6.5ml of dilution
buffer, centrifuged (800g, 10min, gentle deceleration) at room
temperature and transferred into the CellTracks AutoPrep system.
After aspiration of the plasma and dilution buffer layer, anti-
EpCAM-antibody-coated ferrofluids were added. After incubation
and magnetic separation, unbound cells and remaining plasma
were removed, and ferrofluid-labelled cells were re-suspended in
buffer, permeabilised and fluorescently labelled using phycoerythrin-
conjugated anti-cytokeratin antibodies recognising cytokeratins
(predominantly cytokeratins 8, 18 and 19) to specifically identify
epithelial cells; with an antibody against CD45 conjugated with
allophycocyanin to identify WBC and a with nuclear dye (40,6-
diamidino-2-phenylindole, DAPI) to fluorescently label cell nuclei.
The sample was transferred automatically to a cartridge in a
MagNest, in which immunomagnetically labelled cells move to the
surface caused by the strong magnetic field of the MagNest device.
The MagNest was placed on the CellTracks Analyzer II, a four-
colour semi-automated fluorescence microscope, and image
frames covering the entire surface of the cartridge for each of
the four fluorescent filter cubes were captured. The captured
images containing objects that met predetermined criteria were
automatically presented in a web-enabled browser from which
final selection of cells was carried out by the operator. The main
criteria for an object to be defined as a CTC included a round-to-
oval morphology, a visible nucleus (DAPIþ), positive staining for
cytokeratin and negative staining for CD45. Results of cell
enumeration were expressed as the number of cells per 7.5ml of
blood, and a cutoff of X2 CTC was chosen to define the test as
positive. Each sample was analysed independently by two readers
(HE and PV). Questionable interpretations were evaluated again
until consensus was reached.
AdnaTest Breast Cancer Select/Detect
Blood (2 5ml) samples were taken using AdnaCollect blood
collection tubes (AdnaGen, Langenhagen, Germany) and immedi-
ately placed on ice. For each donor, the AdnaTest Breast Cancer
Select/Detect technique was used on two separate blood samples,
according to the manufacturer’s instructions.
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added to 5ml of blood and incubated for 15min at room
temperature (5r.p.m.). After incubation, cells were repeatedly
washed with PBS and lysed by adding a Lysis/Binding buffer
(AdnaGen). The supernatant was recovered.
AdnaTest Breast Cancer Detect mRNA was subsequently recov-
ered by a magnetic separation using Oligo(dT)25 Dynabeads. The
total mRNA/bead mixture (29.5ml) was reverse transcribed using
0.5ml of RNase inhibitor (40Uml
 1; Promega, Madison, WI, USA),
4ml of RT buffer, 4ml of dNTPs and 2ml of Sensiscript Reverse
Transcriptase (Qiagen, Valencia, CA, USA). Reverse transcription
was performed in a one-step reaction (60min at 371C, 5min
at 931C). The mixture was then chilled down on ice and stored
at  201C.
For the analysis of tumour-associated mRNAs, a multiplex PCR
was carried out. The primer mixture consisted of four specific
primer pairs for the amplification of three tumour markers (Muc-1,
HER2 and GA733-2) and one housekeeping gene (Actin). PCR
analyses were carried out in a final volume of 50mlP C Rm i x t u r e ,
containing 8ml of cDNA, 4ml primer mixture (PrimerMix Breast-
Detect; AdnaGen), 25ml of Hot Star Taq Master Mix (Qiagen) and
13ml of distilled water. PCR analyses were performed as follows: pre-
denaturation at 951C for 15min, followed by 35 cycles of
denaturation at 941C, annealing at 601C for 1min, extension at
721C for 1min and a final extension step at 721Cf o r1 0m i n .
For negative controls, mRNA and cDNA were replaced by water
in the reverse transcription and PCR experiments.
Evaluation Visualisation of data was carried out using the
BioAnalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA)
on a DNA 1000 LabChip. For interpretation of the test result, a
fragment of the control gene actin had to occur in each sample
(internal PCR control). The AdnaTest was considered to be
positive if a PCR fragment of at least one tumour-associated
transcript was clearly detected (peak concentration of
40.30ngml
 1). Peaks that were not detected at the above setting
were negative (concentration o0.15ngml
 1). Peaks with an
intermediate concentration of 0.15–0.30ngml
 1 were considered
to be inconclusive. For a participant in this study to be diagnosed
as positive for CTC in blood, both blood samples had to have a
positive result by the AdnaTest.
Quantitative multimarker RT–PCR assay
Total RNA extraction Blood (9ml) was collected from each donor
into VenoSafe EDTA blood collection tubes (Terumo Europe,
Leuven, Belgium). First, blood was passed through a LeukoLOCK
filter (Ambion/Applied Biosystems, Foster City, CA, USA), which
captures the total leukocyte population. RNA in cells captured on
the filter was then stabilised with Ambion RNAlater Solution
(Ambion/Applied Biosystems) and stabilised cells were stored on
the filter at  201C until further use. Total RNA was purified using
the bead capture technology of the LeukoLOCK system (Ambion/
Applied Biosystems) and quantified using the NanoDrop ND-1000
(Thermo Fischer Scientific, Wilmington, DE, USA).
RT–PCR RNA (2mg) was reverse transcribed in a final volume of
100ml using a High Capacity cDNA Archive kit (Applied
Biosystems). All PCR reactions were performed on a 7900HT Fast
Real-time PCR System (Applied Biosystems). Fluorogenic probes
and primer sets for CK-19 and mammaglobin were custom
synthesised by Applied Biosystems and are listed elsewhere (Benoy
et al, 2004). Commercially available probes and primer sets for
ACTB and TBP were used for normalisation (Applied Biosystems).
Fluorogenic PCR analyses were carried out in a reaction volume of
25ml and contained 12.5mlo fTaqMan Gene Expression Master
Mix (Applied Biosystems) and 10ml of cDNA solution. Each
sample was analysed in duplicate and mean Ct values were used for
further analysis.
Table 1 Relations of positive rates by the three CTC detection techniques with clinicopathological variables and other molecular markers in blood
All patients
CellSearch
CTC test AdnaTest
RT–PCR for
CK-19
RT–PCR for
mammaglobin
RT–PCR
CK-19 and/or
mammaglobin
Characteristic N % N % PN % PN % PN % PN % P
ER
Positive 51 71 21 81 0.20 15 94 0.02 15 75 0.63 29 74 0.47 33 73 0.55
Negative 21 29 5 19 1 6 5 25 10 26 12 27
PR
Positive 37 53 13 52 0.84 9 60 0.53 9 47 0.57 21 57 0.49 23 53 0.89
Negative 33 47 12 48 6 40 10 53 16 43 20 47
HER2
Positive 25 33 7 26 0.36 3 19 0.17 4 20 0.14 13 32 0.74 14 30 0.40
Negative 50 67 20 74 13 81 16 80 28 68 33 70
P53
Positive 18 37 6 35 0.89 3 25 0.39 8 53 0.11 10 36 0.86 13 39 0.58
Negative 31 63 11 65 9 75 7 47 18 64 20 61
Disease status
Progressive 46 63 22 81 0.02 12 75 0.22 15 75 0.19 25 64 0.84 30 67 0.41
Non-progressive 27 37 5 19 4 25 5 25 14 36 15 33
CA15.3 levels
a
High (X109U/ml) 34 51 22 85 o0.001 14 87 0.001 15 823 0.001 20 54 0.55 24 56 0.27
Low (o109U/ml) 33 49 4 15 2 13 3 17 17 46 19 44
Abbreviations: CTC¼circulating tumour cell; ER¼oestrogen receptor; PR¼progesterone receptor; RT–PCR¼reverse transcription–PCR. Statistically relevant relations are
presented in bold.
aSerum CA15.3 levels were dichotomised according to the median level in the breast cancer population.
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and TBP expression levels and expressed in relation to a positive
control sample using the 2
 DDCt quantification method (Livak and
Schmittgen, 2001). We use the abbreviation RGE (relative gene
expression) to indicate these measurements. RGE was then
normalised according to the following equation:
NRGE ¼ RGE ðCRNA VRNAÞ=Vext 1=ðCcDNA VPCRÞ
where NRGE is the normalised RGE expressed as relative target
concentration per ml of blood; CRNA the concentration of total
RNA extracted per sample; VRNA the elution volume of RNA
obtained after extraction; Vext the volume of blood extracted;
CcDNA the concentration of cDNA and VPCR the volume of cDNA
solution used for PCR amplification.
Statistical analysis
The Mann–Whitney U-test was used to assess differences between
non-parametrically distributed variables. Correlations between
continuous non-parametric variables were assessed by calculating
Spearman’s rank correlation coefficient or by the k-test in the case
of categorical variables (Landis and Koch, 1977). Differences in
rates of positive samples between the three CTC detection
methods were investigated using the McNemar test. The Pearson’s
w
2-test or, in the case of low frequencies per cell, the Fisher’s exact
method was used to assess the relationship between rates of
positive samples and patient characteristics. A two-sided Pp0.05
was considered to be statistically significant. All statistical
calculations were performed using SPSS, version 11.0 (SPSS,
Chicago, IL, USA).
RESULTS
Detection of CTCs with the CellSearch CTC test
The CellSearch CTC System was used to enumerate CTCs in blood
of 76 MBC patients and 20 healthy volunteers. In this study, 59% of
MBC patients and 10% of healthy controls had at least one
detectable CTC in 7.5ml of blood (Po0.001, Pearson’s w
2-test). For
one patient, the sample quality did not permit an accurate CTC
enumeration. Numbers of CTC were significantly higher in blood
samples of patients with MBC than in healthy controls: the median
number of CTCs detected in 7.5ml of blood was 1 (range, 0–2617)
in MBC patients (N¼75) and 0 (range, 0–1) in controls (N¼20)
(Po0.001, Mann–Whitney U-test) (Figure 1A). Numbers of CTC
did not differ between treated and untreated patients (P¼0.302,
Mann–Whitney U-test): the median number of CTCs in the treated
patient group (N¼59) was 1 (0–2617) and the median number of
CTCs in the untreated patient group (N¼16) was 0.5 (0–153). The
number of patient samples reaching the cutoff level of 2 or more
CTCs in 7.5ml of blood was 36%. Using this approach, we obtained
positive CTC test results by the CellSearch System in 41% of
treated patients and in 19% of untreated patients (P¼0.427,
Pearson’s w
2-test).
Next, we assessed the correlation between CTCs in blood and
tumour progression (Table 1). The median number of CTCs was 1
(range, 0–2617) in patients with progressive disease (N¼46) and 0
(range, 0–39) in non-progressive patients (N¼26) (P¼0.004,
Mann–Whitney U-test). Furthermore, a positive correlation
between the number of CTCs and serum CA15.3 levels (r¼0.669,
Po0.001) or patients’ age was observed (r¼0.376, P¼0.001).
No associations were found between the presence of two
or more CTCs and ER, PR, HER2 or P53 expression by the
primary tumour.
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Figure 1 (A) Number of CTCs detected in 7.5ml of blood taken from
healthy controls (N¼20) and metastatic breast cancer (MBC) patients
(N¼76) when samples were analysed with the CellSearch CTC test. (B)
Normalised relative gene expression levels of CK-19 detected in blood
from MBC patients (N¼76) when samples were analysed using a real-time
RT-PCR assay. (C) Normalised relative gene expression levels of
mammaglobin detected in blood from MBC patients (N¼76) when
samples were analysed using a real-time RT-PCR assay. Treated: patients
with MBC during treatment. Untreated: patients with MBC receiving no
treatment.
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Cancer Select/Detect
The AdnaTest Breast Cancer Detect is considered positive if a PCR
fragment of at least one tumour-associated transcript (Muc-1,
GA733-2 or HER2) is clearly detected (peak concentration
of 40.30ngml
 1 with the BioAnalyzer 2100), it is considered
inconclusive if peaks have an intermediate concentration
(0.15–0.30ngml
 1) and as negative if peak concentrations are
o0.15ngml
 1. Using these criteria, 18 volunteers in the healthy
control population (N¼20) were diagnosed as negative by
the AdnaTest, 1 healthy control had a single positive blood sample
and 1 healthy control had inconclusive test results. Of 76 MBC
patients, 16 patients (22%) had two positive blood samples,
7 patients (9%) had only one positive blood sample and 51 patients
(68%) had no positive blood samples. For two patients, an
inconclusive test result was observed and these were left out for
further analysis. The frequency of a positive test result (two
positive blood samples) was significantly higher in MBC patients
than in healthy controls, 22 vs 0% (P¼0.03, Pearson’s w
2-test).
No significant differences were observed between treated and
untreated patient groups.
A positive outcome with the AdnaTest was associated with high
CA15.3 levels (relative to the median level in the patient
population) (P¼0.001, Pearson’s w
2-test) but not with tumour
progression (P¼0.22, Pearson’s w
2-test). In addition, no associa-
tion was found between tumour progression and the number of
positive blood samples (P¼0.35, Pearson’s w
2-test). The outcome
of the AdnaTest correlated with the ER status of the primary
tumour (P¼0.02, Pearson’s w
2-test), but not with PR, HER2 or P53
status. Data are summarised in Table 1.
Detection of CTCs with a quantitative multimarker
RT–PCR assay
Sensitivity and specificity of the quantitative real-time RT-PCR
assay for CK-19 and mammaglobin have previously been described
(Benoy et al, 2004). The median NRGE levels in MBC patients
(N¼76) were 0.105 (range, 0–163.15) for CK-19 and 0.001 (range,
0–120.44) for mammaglobin (Figure 1B and C). No significant
differences in median NRGE levels for CK-19 or mammaglobin
were observed between treated and untreated patient groups
(P¼0.87 and 0.91, Mann–Whitney U-test). The median NRGE
levels of both mRNA markers were significantly correlated
(r¼0.321, P¼0.005). NRGE levels of CK-19 or mammaglobin
correlated with CA15.3 levels (r¼0.481, Po0.001 and r¼0.386,
P¼0.001), but not with patients’ age.
We also analysed the PCR results for CK-19 as categorical
variables, by establishing a cutoff value for positivity that
corresponded to 100% specificity (maximal NRGE values mea-
sured in the control population). On this basis, 20 of 76 (26%)
patients were positive for CK-19. As no PCR signals for
mammaglobin were detected in any of the control samples, a
patient sample was considered positive when a PCR signal for
mammaglobin was detected. Mammaglobin expression was
measurable in 41 of 76 (54%) MBC patients. Of the 76 blood
samples from MBC patients, 14 (18%) were positive for both CK-19
and mammaglobin, 33 (43%) were positive for only one mRNA
marker and 29 (38%) were negative for both CK-19 and
mammaglobin. A positive result for CK-19 and/or mammaglobin
mRNA expression was found in 69% of untreated patients (N¼16)
and in 60% of treated patients (N¼60) (P¼0.52, Pearson’s
w
2-test). There was no significant concordance between samples
either positive or negative for CK-19 and mammaglobin (k¼0.16,
P¼0.09, k-test).
Next, we analysed the relationship between CTC detected by
RT–PCR for CK-19 or mammaglobin and tumour progression
(Table 1). The detection rate of CK-19þ or mammaglobinþ
blood samples was not associated with tumour progression
(P¼0.19 and 0.84, Pearson’s w
2-test). No associations were found
between CK-19 or mammaglobin expression and any of the
clinicopathological variables (ER, PR, HER2 and P53).
Comparison between the three CTC detection methods
Quantitatively, higher CTC numbers by the CellSearch System and
higher NRGE levels for CK-19 were observed in blood samples
defined as positive by the AdnaTest than in negative samples
(Po0.001 and 0.002, Mann–Whitney U-test). For mammaglobin
expression, no differences were observed (P¼0.09, Mann–
Whitney U-test). Furthermore, we observed a good correlation
between the number of CTCs detected with the CellSearch CTC test
and the NRGE levels of CK-19 (r¼0.453, Po0.001) or mamma-
globin (r¼0.477, Po0.001) by RT–PCR (Figure 2).
According to the McNemar test, a significant difference in posi-
tivity was observed by the CellSearch CTC test and the AdnaTest
(36 vs 22%, P¼0.013). Patients with MBC were more likely to be
positive for CK-19 and/or mammaglobin while using real-time RT–
PCR than using the CellSearch CTC test (63 vs 36%, P¼0.001,
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Figure 2 Correlation between the number of circulating tumour cells by the CellSearch System and the normalised relative gene expression levels of
CK-19 (A) or mammaglobin (B) by RT–PCR in MBC patients.
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sMcNemar test) or the AdnaTest (61% vs 22%, Po0.001, McNemar
test).
Concordant samples were defined as those in which the sample
from a patient was reported as either positive or negative by both
the detection techniques being compared. As a result, the
concordance between samples analysed by the CellSearch CTC
test and the AdnaTest was moderate (k¼0.543, Po0.001, k-test).
Agreement between both detection techniques was observed in
81% of blood samples. When the CellSearch CTC test was
compared with RT–PCR assays for CK-19 and mammaglobin,w e
observed agreement percentages of 72 and 60%, respectively
(k¼0.356, P¼0.002 and k¼0.220, P¼0.04, k-test). Agreement
between the AdnaTest and RT–PCR assays for CK-19 and
mammaglobin was observed in 78 and 53% of blood samples,
respectively (k¼0.415, Po0.001 and k¼0.082, P¼0.375, k-test).
Data are summarised in Table 2. For eight MBC patients (10%), a
positive test result was obtained using the three methods.
DISCUSSION
Despite important advances in the early diagnosis and treatment,
metastatic disease occurs in about 50% of cases with apparently
localised breast cancer, and even 30% of patients with node-
negative disease will develop distant metastases (Braun et al, 2001).
Staging of carcinoma patients in clinical practice is based on
tumour characteristics such as tumour size, tumour grade,
lymphovascular involvement, the presence of metastases in
regional lymph nodes at the time of primary surgery, steroid
receptor status and human epidermal growth factor receptor 2
amplification (Singletary et al, 2002). The assessment of CTCs in
peripheral blood samples is not considered to be a routine
procedure in the clinical management of breast cancer for several
reasons (Riethdorf et al, 2007). Most notably, the variable technical
approaches used, the high inter-laboratory differences in the
number of millilitres of blood analysed, the quality of sensitivity
and specificity tests, the number of patients vs controls and data
interpretation make it very difficult to draw firm conclusions
about the impact of CTC detection in cancer prognosis and follow-
up (Paterlini-Brechot and Benali, 2007). The primary objective of
this study was to compare three different techniques for the
detection of CTC in blood from patients with MBC: (1) the
CellSearch System, which represents an automated, standardised
and regulatory-approved system for the immunocytochemical
detection and quantification of CTCs in blood; (2) the AdnaTest
Breast Cancer Select/Detect, which involves the detection of
tumour-associated transcripts by RT–PCR after an immunomag-
netic enrichment of tumour cells and (3) an in-house developed
multimarker real-time RT-PCR assay, which involves the quanti-
fication of tumour-associated transcripts by real-time RT-PCR
after enrichment of peripheral blood mononuclear cells by
filtration. Technical details of the three detection techniques are
summarised in Table 3.
We observed significant differences in the detection frequencies
of CTCs among the three assays. Using the CellSearch CTC test, we
found that the number of CTCs in our survey of MBC patients
ranged from 0 to 2617. In 59% of blood samples, at least one CTC
was detected and in 36% of blood samples, two or more CTCs were
detected. In contrast, none of the blood samples in the control
population contained two or more CTCs, which corresponds to a
specificity of 100%. Using the same cutoff value, Allard et al (2004)
obtained a positivity rate of 37% in a pooled analysis of 1316 blood
samples obtained from 422 patients at different occasions.
However, when analysing treated and untreated patients sepa-
rately, only 19% of the untreated patients (N¼16) included in our
study had two or more CTC per 7.5ml blood, which is
considerably lower than the numbers found by Cristofanilli et al
(2004) in 177 patients with MBC before the start of a new line of
treatment (61%) (Table 4). The reason for this discrepancy
remains unclear but could be because of the small sample size of
untreated patients in our study. When using the AdnaTest, none
of the blood samples of healthy subjects were found to be positive.
A relatively low rate of two positive blood samples (22%) was
observed in the patient population. For comparison, Zieglschmid
et al (2007a) reported the presence of CTCs in 69% of blood
samples from MBC patients using the same technique. However, in
Table 2 Concordances between the three CTC detection techniques
K coefficient P-value Degree of agreement Agreement (%)
Comparison with the CellSearch CTC test
AdnaTest 0.543 o0.001 Moderate 81
RT–PCR for CK-19 0.356 0.002 Fair 72
RT–PCR for mammaglobin 0.220 0.04 Fair 60
RT–PCR for CK-19 and/or mammaglobin 0.203 0.04 Fair 57
Comparison with the AdnaTest
RT–PCR for CK-19 0.415 o0.001 Moderate 78
RT–PCR for mammaglobin 0.082 0.37 Slight 53
RT–PCR for CK-19 and/or mammaglobin 0.109 0.189 Slight 50
Abbreviations: CTC¼circulating tumour cell; ER¼oestrogen receptor; PR¼progesterone receptor; RT–PCR¼reverse transcription–PCR.
Table 3 Comparison of the three detection techniques
Assay Blood volume per test Principle of CTC enrichment Method of detection
CellSearch 7.5ml Immunomagnetic – EpCAM Visual confirmation of fluorescently labeled cells
(CK+/DAPI+/CD45 )
AdnaTest 2 5ml Immunomagnetic – 2 anti-Muc-1 Ab
and 1 anti-EpCAM Ab
Multiplex RT–PCR for HER2, Muc-1 and EpCAM
CK-19/MAM RT–PCR 9ml Size filtration of PB mononuclear cells Multiplex real-time quantitative RT–PCR for CK-19
and mammaglobin
Abbreviations: CTC¼circulating tumour cell; RT–PCR¼reverse transcription–PCR.
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sa recent study by Aktas et al (2009) investigating the expression of
EMT and stem cell markers in CTCs detected with the AdnaTest,
CTCs were found in 69 of 226 (31%) blood samples taken from
patients with MBC (Aktas et al, 2009; Table 4). Using our
previously developed quantitative real-time RT-PCR assay,
we measured normalised RGE levels in cancer patients ranging
from 0 to 163 for CK-19 and from 0 to 120 for mammaglobin.
Low levels of CK-19 mRNA were also found in the blood of
healthy donors. The detection of CK-19 in healthy donors by
RT–PCR has been attributed to an illegitimate transcription of the
CK-19 gene in peripheral blood mononuclear cells (Novaes
et al, 1997) and/or to an increased secretion of cytokines that
can induce transcription of tissue-specific genes in peripheral
blood leukocytes (Chelly et al, 1989; Jung et al, 1998). To solve this
issue, we chose a cutoff for positivity, which corresponded to a
specificity of 100%. On this basis, 26% of patient samples were
positive for CK-19 mRNA. As mammaglobin expression was never
detected in blood samples from healthy controls, patient samples
were called positive when a PCR signal for mammaglobin mRNA
was detected. On this basis, 54% of patient samples were positive
for mammaglobin expression. Notably, 61% of patients were
positive for at least one of the two transcript markers, which shows
the benefit of using more than one target for RT–PCR
amplification. The sensitivity of the multimarker real-time
RT-PCR assay significantly exceeded that of the CellSearch CTC
test and that of the AdnaTest.
Aside from the relative sensitivities and specificities of the
different techniques, we were also interested in the correlations
between techniques and their concordance. We observed
significant correlations between cell numbers detected by the
CellSearch System and normalised RGE levels of CK-19 and
mammaglobin mRNA by real-time RT-PCR. When a cutoff for
positivity was established, the concordance between the CellSearch
System and the real-time RT-PCR assay was 72 and 60%,
depending on the transcript marker. Overall, the concordances
between techniques ranged from 53% (for AdnaTest and
mammaglobin RT–PCR) to 81% (for AdnaTest and CellSearch
System). Thus, samples being called positive or negative differed
according to the CTC detection technology. The low concordance
between our real-time RT-PCR assay and the AdnaTest may be
explained by several reasons: (1) the AdnaTest is based on an
immunomagnetic enrichment of tumour cells by epithelial and
tumour-associated antigens, whereas in our assay, filter technology
is used to remove red blood cells; (2) different RNA isolation and
RT protocols are used in both assays; (3) the presence of tumour
cells is indicated by different transcript markers and (4) in the
AdnaTest, PCR products are visualised using microfluidic gel
electrophoresis after which peak concentrations are measured,
whereas the real-time PCR assay allows for a more sensitive
quantification of mRNA expression levels by which also the exact
amount of background transcription can be assessed.
Although, in general, approaches based on RT–PCR have a high
sensitivity for the detection of CTC, an important limitation of
these methods is that these cannot quantify the number of CTCs
and no morphological evaluation of cells can be obtained.
Furthermore, it remains unclear whether the minute tumour
dissemination detected by PCR is capable of causing clinically
relevant distant metastasis. In contrast to RT–PCR assays, the
CellSearch CTC test allows for the counting of target cells.
Advantages of the CellSearch System are its capability of
standardising pre-analytical preparation of CTCs, the use of CTC
preservative tubes that allow stabilisation of CTCs for up to 96h
and the inclusion of a positive control for assuring proper
performance on a daily or run-to-run basis. All these features are
beneficial in a multi-centre setting in clinical trials. One of the
limitations of the CellSearch System, however, is the anti-EpCAM
antibody-based enrichment strategy. Several authors reported the
heterogeneous expression of EpCAM in mammary carcinomas
(Thurm et al, 2003) and downregulation of EpCAM has been
reported for disseminated tumour cells in bone marrow and
CTCs in peripheral blood (Thurm et al, 2003; Rao et al, 2005).
Recently, Deng et al (2008) showed that CTC enrichment with
anti-cytokeratin antibodies, in combination with anti-EpCAM
antibodies, significantly enhances assay sensitivity.
Summarising the results of this study, our multimarker
quantitative RT-PCR assay showed superior sensitivity for the
detection of CTCs in MBC compared with the CellSearch System
and the AdnaTest. However, further studies are needed to clarify
the prognostic value of this highly sensitive and standardised
qRT-PCR approach for CTC detection in peripheral blood of
patients with breast cancer.
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